Twenty-five percent of adults with atopic dermatitis report the disease started in adulthood. Yet, diagnosing adult-onset atopic dermatitis can challenge even expert clinicians. Here's what you need to know.
The oral selective JAK inhibitor baricitinib may be an effective, safe option for patients with moderate-to-severe atopic dermatitis (AD), according to results from two phase 3 clinical trials. (©TYLim/Shutterstock)